Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cardamom, derived from the seeds of the plant *Elettaria cardamomum*, is being investigated for its therapeutic potential in managing atopic dermatitis (DOID_3310) due to its anti-inflammatory and immunomodulatory properties. The active constituents of cardamom, including essential oil components like 1,8-cineole (eucalyptol) and the chalcone cardamonin, are thought to modulate the immune response by suppressing the production of pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6. In the context of atopic dermatitis, cardamom extracts have demonstrated the ability to inhibit Th2-mediated inflammatory pathways and reduce oxidative stress, which are key drivers of skin barrier dysfunction and chronic inflammation. While primarily used as a spice and dietary supplement, its extracts are being explored in preclinical and pilot studies for their efficacy in reducing skin lesions and systemic inflammatory markers associated with atopic conditions.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cardamom.